Perceptive Advisors’s Arena Pharmaceuticals Inc ARNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-500,000
Closed -$46.5M 159
2021
Q4
$46.5M Buy
+500,000
New +$32.9M 0.72% 35
2021
Q2
Sell
-575,007
Closed -$39.9M 167
2021
Q1
$39.9M Hold
575,007
0.5% 51
2020
Q4
$44.2M Sell
575,007
-50,122
-8% -$3.76M 0.47% 49
2020
Q3
$46.8M Sell
625,129
-470,000
-43% -$31.3M 0.68% 39
2020
Q2
$68.9M Buy
1,095,129
+420,000
+62% +$23.1M 1.12% 23
2020
Q1
$28.4M Sell
675,129
-278,000
-29% -$12.7M 0.74% 35
2019
Q4
$43.3M Hold
953,129
0.86% 29
2019
Q3
$43.6M Sell
953,129
-427,042
-31% -$24M 1.18% 24
2019
Q2
$80.9M Sell
1,380,171
-20,000
-1% -$1.03M 1.86% 13
2019
Q1
$62.8M Sell
1,400,171
-30,000
-2% -$1.38M 1.77% 16
2018
Q4
$55.6M Buy
1,430,171
+63,193
+5% +$2.48M 2.12% 11
2018
Q3
$62.9M Buy
1,366,978
+525,000
+62% +$21.3M 1.68% 18
2018
Q2
$36.7M Buy
841,978
+670,000
+390% +$28.8M 0.96% 33
2018
Q1
$6.79M Buy
171,978
+150,000
+683% +$5.83M 0.19% 74
2017
Q4
$747K Buy
+21,978
New +$626K 0.02% 107

Perceptive Advisors's ARNA Position: Q1 2022 in Review

Perceptive Advisors sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 500,000 shares — an estimated $46.5M sold.

Perceptive Advisors first reported a position in ARNA in Q4 2017 and held it in 15 quarters. The position peaked at $80.9M in Q2 2019. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.

  • Perceptive Advisors reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
  • Perceptive Advisors sold 500,000 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $46.5M.
  • Perceptive Advisors first reported a position in Arena Pharmaceuticals Inc in Q4 2017 and held it in 15 quarters.
  • Perceptive Advisors's Arena Pharmaceuticals Inc position peaked at $80.9M in Q2 2019.
  • 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.

Based on Perceptive Advisors's 13F filing for Q1 2022, filed 16 May 2022.